Reducing the risk of psoriatic arthritis

[Fred]

Is it time to rethink using bio treatments earlier for psoriatic arthritis (PsA) ?

Quote:

---

A major strength of the study lies in its thoughtful design, which addresses two key sources of bias that have affected previous analyses: protopathic bias and confounding-by-indication. By excluding PsA cases diagnosed within 1 year of biologic initiation, the authors reduce the likelihood that early, subclinical joint symptoms prompted the switch to biologics. Similarly, by restricting the baseline population to patients who had all received phototherapy—used here as a proxy for moderate-to-severe psoriasis—the study ensures a more comparable starting point between cohorts. This is a notable improvement over earlier claim-based studies that compared biologic users with patients treated only with topicals or mild systemic agents, inadvertently mixing populations with very different baseline risks.

The results are compelling: The fully adjusted hazard ratio for PsA development among biologic users was 0.66, indicating a 34% relative risk reduction. This effect persisted across multiple sensitivity analyses, including age-, sex- and ethnicity-matched cohorts. Although observational data cannot establish causality, the consistency of the findings strengthens the argument that biologics may modify the natural history of psoriatic disease.

Biologically, this hypothesis is plausible. Psoriasis and PsA share overlapping immunopathogenic pathways, particularly involving TNF-α, IL-17 and IL-23. Subclinical entheseal inflammation is well-documented in psoriasis patients, even in the absence of joint symptoms. Early suppression of these inflammatory pathways may theoretically prevent progression to clinical PsA. Indeed, imaging studies have shown that biologics can reduce enthesitis and synovitis detectable by ultrasound or MRI, even in patients without established PsA.

However, several limitations warrant consideration. First, the use of phototherapy as a surrogate for disease severity, while pragmatic, is imperfect; treatment selection is influenced by patient preference, access and physician practice patterns. Second, claims databases lack granular clinical data such as PASI scores, body surface area, nail involvement or family history—factors known to influence PsA risk. Third, although PsA diagnoses were restricted to rheumatologists, misclassification remains possible. Finally, the study does not differentiate between biologic classes; whether IL-23 inhibitors, IL-17 inhibitors, or TNF inhibitors differ in their preventive potential remains debatable.

Despite these limitations, the study adds weight to a growing body of evidence suggesting that early systemic intervention may alter the trajectory of psoriatic disease. If confirmed in prospective studies, this could have meaningful implications for clinical practice. Dermatologists may increasingly consider early biologic therapy not only to control skin inflammation but also to reduce the long-term burden of PsA, a condition associated with irreversible joint damage, disability and reduced quality of life.

Future research should focus on prospective cohorts with standardized clinical assessments, imaging biomarkers and stratification by biologic class. Randomized controlled trials designed specifically to evaluate PsA prevention—although challenging—would provide the highest level of evidence. Until then, the findings by Miao et al. represent an important step towards understanding how timely intervention may reshape the natural history of psoriatic disease.

Source: onlinelibrary.wiley.com

*Funding: Università degli Studi di Verona

Biological Treatments For Psoriasis

What is psoriatic arthritis

[Caroline]

Is it time to rethink using bio treatments earlier for psoriatic arthritis (PsA) ?

I do think so of course. Seems very obvious for me.

A major strength of the study lies in its thoughtful design, which addresses two key sources of bias that have affected previous analyses: protopathic bias and confounding-by-indication. By excluding PsA cases diagnosed within 1 year of biologic initiation, the authors reduce the likelihood that early, subclinical joint symptoms prompted the switch to biologics. Similarly, by restricting the baseline population to patients who had all received phototherapy—used here as a proxy for moderate-to-severe psoriasis—the study ensures a more comparable starting point between cohorts. This is a notable improvement over earlier claim-based studies that compared biologic users with patients treated only with topicals or mild systemic agents, inadvertently mixing populations with very different baseline risks.

There is another quirk in the start. It is assumed that every PsA patient also has Psoriasis, which is not true for about 10% of the PsA population.
And…. Mild systemic agents?  What are those? Topicals do not work for PsA, so perhaps they mean MTX?? But that is by long NOT MILD….. not to speak of Acetretin or Cyclosporin, they are worse than MTX.
The only thing that could be seen as mild is DMF, but that is hardly used outside of the Netherlands and Germany.

The results are compelling: The fully adjusted hazard ratio for PsA development among biologic users was 0.66, indicating a 34% relative risk reduction. This effect persisted across multiple sensitivity analyses, including age-, sex- and ethnicity-matched cohorts. Although observational data cannot establish causality, the consistency of the findings strengthens the argument that biologics may modify the natural history of psoriatic disease.

This is really vague… 34% relative risk reduction against What?
The conclusion I see as obvious… we already KNOW that biologics at least heavily change the natural history of your Psoriasis, so why the “may modify” and why are they not referring to Psoriatic Arthritis.

Biologically, this hypothesis is plausible. Psoriasis and PsA share overlapping immunopathogenic pathways, particularly involving TNF-α, IL-17 and IL-23. Subclinical entheseal inflammation is well-documented in psoriasis patients, even in the absence of joint symptoms. Early suppression of these inflammatory pathways may theoretically prevent progression to clinical PsA. Indeed, imaging studies have shown that biologics can reduce enthesitis and synovitis detectable by ultrasound or MRI, even in patients without established PsA.

Plausible ????? Psoriasis and Psoriatic Arthritis are the “same” disease… it is LOGICAL, that the hypothesis is valid.
Far too hesitating, as we already know much more. At least here at PC.

However, several limitations warrant consideration. First, the use of phototherapy as a surrogate for disease severity, while pragmatic, is imperfect; treatment selection is influenced by patient preference, access and physician practice patterns. Second, claims databases lack granular clinical data such as PASI scores, body surface area, nail involvement or family history—factors known to influence PsA risk. Third, although PsA diagnoses were restricted to rheumatologists, misclassification remains possible. Finally, the study does not differentiate between biologic classes; whether IL-23 inhibitors, IL-17 inhibitors, or TNF inhibitors differ in their preventive potential remains debatable.

I surely get that misclassification can happen because of diagnoses by rheumatologists, personally I have more faith in the diagnoses of dermatologists.
Would indeed have been smart to differentiate between the different biologics. But I assume that in the records of the research this is all still available so the study can be enhanced.

Despite these limitations, the study adds weight to a growing body of evidence suggesting that early systemic intervention may alter the trajectory of psoriatic disease. If confirmed in prospective studies, this could have meaningful implications for clinical practice. Dermatologists may increasingly consider early biologic therapy not only to control skin inflammation but also to reduce the long-term burden of PsA, a condition associated with irreversible joint damage, disability and reduced quality of life.

Okay, as far as I read, they come to the conclusion that the early onset of biologics may be smart. That is at least a good and sensible result. Again quite logical, but good to have it proven.

Future research should focus on prospective cohorts with standardized clinical assessments, imaging biomarkers and stratification by biologic class. Randomized controlled trials designed specifically to evaluate PsA prevention—although challenging—would provide the highest level of evidence. Until then, the findings by Miao et al. represent an important step towards understanding how timely intervention may reshape the natural history of psoriatic disease.

I do not understand why you should need the “highest level of evidence”, even lesser evidence is enough when you combine it with experience and common sense..
Why for heavens sake does everything have to be “scientifically evidence based”, before you go and use it. Why can’t you follow experience and common sense thinking.
Why is more research necessary, Just practice and follow.
There are already studies going on, like the HPOS study and the iProlepsis study, both international studies..

Source: onlinelibrary.wiley.com

*Funding: Università degli Studi di Verona

Biological Treatments For Psoriasis

What is psoriatic arthritis

[mataribot]

Cost & Risk/Reward is probably part of the reason they’re not actually suggesting something, or maybe it’s another garbage meta study. However, we do need to some caution when prescribing medications. We know that Enbrel causes flares in IBD, but Humira does not. We also know that there’s an increase risk cancer with TNFs in the younger population.

[Waine]

There is another quirk in the start. It is assumed that every PsA patient also has Psoriasis, which is not true for about 10% of the PsA population.
And…. Mild systemic agents?  What are those? Topicals do not work for PsA, so perhaps they mean MTX?? But that is by long NOT MILD….. not to speak of Acetretin or Cyclosporin, they are worse than MTX.
The only thing that could be seen as mild is DMF, but that is hardly used outside of the Netherlands and Germany.

I think they're saying this study changed the nature of people studied excluded patients with PsD treated with Mild or Topic treatments, and instead used those who had received Phototherapy. I have no idea what a "Mild Systemic agent" might be, none that I ever had were mild, but then I was only ever treated for PsA and never for PsD. My PsD was low enough that over the counter therapeutic shampoos and ointments were sufficient. My PsA not!